SEC Info - Achieve Life Sciences, Inc. - ‘10-Q’ for 6/30/22

SEC Info℠

Home

Help

Please Sign In

Achieve Life Sciences, Inc. – ‘10-Q’ for 6/30/22 – ‘R10’

On: Thursday, 8/11/22, at 4:11pm ET · For: 6/30/22 · Accession #: 1564590-22-29122 · File #: 33-80623

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/11/22  Achieve Life Sciences, Inc.       10-Q        6/30/22   60:7.3M                                   ActiveDisclosure/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   2.15M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 3: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 9: R1          Document and Entity Information                     HTML     75K 
10: R2          Consolidated Balance Sheets (Unaudited)             HTML    118K 
11: R3          Consolidated Balance Sheets (Parenthetical)         HTML     39K 
                (Unaudited)                                                      
12: R4          Consolidated Statements of Loss and Comprehensive   HTML     69K 
                Loss (Unaudited)                                                 
13: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     84K 
14: R6          Consolidated Statements of Stockholder's Equity     HTML     86K 
                (Unaudited)                                                      
15: R7          Nature of Business, Basis of Presentation and       HTML     28K 
                Going Concern Uncertainty                                        
16: R8          Accounting Policies                                 HTML     23K 
17: R9          Government Grant                                    HTML     23K 
18: R10         Intangibles                                         HTML     62K 
19: R11         License Agreements                                  HTML     27K 
20: R12         Fair Value Measurements                             HTML    132K 
21: R13         Convertible Debt                                    HTML     58K 
22: R14         Common Stock                                        HTML    207K 
23: R15         Commitments and Contingencies                       HTML    128K 
24: R16         Intangibles (Tables)                                HTML     62K 
25: R17         Fair Value Measurements (Tables)                    HTML    149K 
26: R18         Convertible Debt (Tables)                           HTML     70K 
27: R19         Common Stock (Tables)                               HTML    186K 
28: R20         Commitments and Contingencies (Tables)              HTML    125K 
29: R21         Nature of Business, Basis of Presentation and       HTML     43K 
                Going Concern Uncertainty - Additional Information               
                (Detail)                                                         
30: R22         Government Grant - Additional Information           HTML     31K 
                (Details)                                                        
31: R23         Intangibles - Additional Information (Detail)       HTML     29K 
32: R24         Intangibles - Components of Intangible Assets       HTML     28K 
                (Detail)                                                         
33: R25         Intangibles - Estimated Future Amortization         HTML     30K 
                Expense Related to Intangible Assets (Detail)                    
34: R26         License Agreements - Additional Information         HTML     27K 
                (Detail)                                                         
35: R27         Fair Value Measurements - Additional Information    HTML     24K 
                (Detail)                                                         
36: R28         Fair Value Measurements - Summary of Assets         HTML     30K 
                Measured at Fair Value on Recurring Basis (Detail)               
37: R29         Fair Value Measurements - Summary of Cash           HTML     27K 
                Equivalents (Detail)                                             
38: R30         Fair Value Measurements - Schedule of Aggregate     HTML     27K 
                Fair Value of Principal Amount of Convertible Debt               
                (Detail)                                                         
39: R31         Convertible Debt - Additional Information           HTML     73K 
                (Details)                                                        
40: R32         Convertible Debt - Schedule of Convertible Debt     HTML     30K 
                Balance (Details)                                                
41: R33         Common Stock - Authorized - Additional Information  HTML     27K 
                (Detail)                                                         
42: R34         Common Stock - Issued and Outstanding Shares -      HTML     57K 
                Additional Information (Detail)                                  
43: R35         Common Stock - Stock Options - Additional           HTML    100K 
                Information (Detail)                                             
44: R36         Common Stock - Summary of Stock Options Activity    HTML     34K 
                (Detail)                                                         
45: R37         Common Stock - Summary of Fair Value of Each Stock  HTML     29K 
                Award for Employees and Directors (Detail)                       
46: R38         Common Stock - Summary of Share-Based Compensation  HTML     27K 
                Expense for Stock Options, Restricted Stock and                  
                Employee Share Purchase Plan (Detail)                            
47: R39         Common Stock - Restricted Stock Unit Awards -       HTML     30K 
                Additional Information (Detail)                                  
48: R40         Common Stock - Summary of Restricted Stock Unit     HTML     37K 
                Award Activity (Detail)                                          
49: R41         Common Stock - Employee Share Purchase Plan -       HTML     24K 
                Additional Information (Detail)                                  
50: R42         Common Stock - Summary of Outstanding Warrants      HTML     52K 
                (Detail)                                                         
51: R43         Common Stock - Common Stock Warrants - Additional   HTML     31K 
                Information (Detail)                                             
52: R44         Commitments and Contingencies - Summary of          HTML     25K 
                Contractual Obligations (Detail)                                 
53: R45         Commitments and Contingencies - Additional          HTML     68K 
                Information (Detail)                                             
54: R46         Commitments and Contingencies - Summary of Future   HTML     26K 
                Minimum Annual Lease Payments (Detail)                           
55: R47         Commitments and Contingencies - Summary of Other    HTML     28K 
                Information Related to Leases (Detail)                           
58: XML         IDEA XML File -- Filing Summary                      XML    109K 
56: XML         XBRL Instance -- achv-10q_20220630_htm               XML   1.57M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     98K 
 5: EX-101.CAL  XBRL Calculations -- achv-20220630_cal               XML    110K 
 6: EX-101.DEF  XBRL Definitions -- achv-20220630_def                XML    496K 
 7: EX-101.LAB  XBRL Labels -- achv-20220630_lab                     XML    967K 
 8: EX-101.PRE  XBRL Presentations -- achv-20220630_pre              XML    710K 
 4: EX-101.SCH  XBRL Schema -- achv-20220630                         XSD    150K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              288±   461K 
60: ZIP         XBRL Zipped Folder -- 0001564590-22-029122-xbrl      Zip    350K

‘R10’ — Intangibles

This is an IDEA Financial Report. [ Alternative Formats ]

Intangibles

6 Months Ended

Jun. 30, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Intangibles

4. INTANGIBLES

All of our intangible assets are subject to amortization and are amortized using the straight-line method over their estimated useful life.

We acquired license and supply agreements in relation to cytisinicline upon the acquisition of Extab Corporation, or Extab, on May 18, 2015. The agreements were determined to have a fair value of $3.1 million with an estimated useful life of 14 years.

The components of intangible assets were as follows:

	June 30, 2022							December 31, 2021
	Gross Carrying		Accumulated			Net Carrying		Gross Carrying		Accumulated			Net Carrying
	Value		Amortization			Value		Value		Amortization			Value
License Agreements	$	3,117	$	(1,587	)	$	1,530	$	3,117	$	(1,476	)	$	1,641

For the three and six months ended June 30, 2022, and 2021 we recorded license agreement amortization expense of $0.1 million and $0.1 million, respectively. The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2022:

Year Ending December 31,
2022		111
2023		223
2024		223
Thereafter		973
Total	$	1,530

We evaluate the carrying amount of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful life or that indicate the asset may be impaired. We conducted an analysis of potential impairment indicators

for long lived assets, including the license and supply agreements for the active pharmaceutical ingredient cytisinicline, and concluded that there were no indicators of impairment identified as of June 30, 2022.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

	12/31/22
Filed on:	8/11/22	8-K
For Period end:	6/30/22
	12/31/21	10-K
	5/18/15
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/12/23  Achieve Life Sciences, Inc.       424B7                  1:173K                                   Donnelley … Solutions/FA
12/29/22  Achieve Life Sciences, Inc.       S-3                    4:276K                                   Donnelley … Solutions/FA

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/27/22  Achieve Life Sciences, Inc.       8-K:1,2,8,9 4/26/22   14:3.8M                                   ActiveDisclosure/FA

↑Top

Filing Submission 0001564590-22-029122 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)